Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The collaborative reanalysis

Journal of Family Planning and Reproductive Health Care

Volumn 37, Issue 2, 2011, Pages 103-109

  Shapiro, Samuel ^a   Farmer, Richard D T ^b   Seaman, Helen ^b,c   Stevenson, John C ^d   Mueck, Alfred O ^e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c Freelance Medical Writer   (United Kingdom)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ANXIETY; ARTICLE; BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CASE CONTROL STUDY; CONFOUNDING VARIABLE; DRUG INDUCED CANCER; HORMONE SUBSTITUTION; HUMAN; INTERNAL CONSISTENCY; MAMMOGRAPHY; MEDICAL INFORMATION; META ANALYSIS (TOPIC); RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CAUSALITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; META-ANALYSIS AS TOPIC; RISK FACTORS; TIME FACTORS; WOMEN'S HEALTH;

EID: 79955569021     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc.2011.0078     Document Type: Article

References (40)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
2. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
3. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-323.
4. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
5. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.
6. Susser M. Causal Thinking in the Health Sciences. New York, NY: Oxford University Press, 1979.
7. US Department of Health, Education and Welfare: Public Health Service. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (Public Health Service Publication No. 11030). Washington, DC: U.S. Government Printing Office, 1964.
8. Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991;133:635-648.
9. Shapiro S. Meta-analysis/Shmeta-analysis. Am J Epidemiol 1994;140:771-778.
10. Greenland S. Can meta-analysis be salvaged? Am J Epidemiol 1994;140:783-787.
11. Petitti DB. Of babies and bathwater. Am J Epidemiol 1994;140:779-782.
12. Petitti D. Meta-Analysis, Decision Analysis and Cost-Effectiveness in Medicine: Methods for Quantitative Synthesis in Medicine (2nd edn). New York, NY: Oxford University Press, 1994.
13. Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol 1997;50:223-229.
14. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052-2060. (Pubitemid 41418488)
15. Mueck AO, Seeger H, Shapiro S. Risk of breast cancer during hormone replacement therapy. Horm Mol Biol Clin Invest 2011;3:329-339.
16. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 1968;41:665-681.
17. Welch HG, Black WC. Using autopsy series to estimate the disease 'reservoir' for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-1028.
18. Santen RJ. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Womens Health (Lond Engl) 2008;4:207-210.
19. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl. 1):S7-S66.
20. Skegg DC. Potential for bias in case-control studies of oral contraceptives and breast cancer. Am J Epidemiol 1988;127:205-212. (Pubitemid 18056374)
21. Morabia A, Szklo M, Stewart W, et al. Consistent lack of association between breast cancer and oral contraceptives using either hospital or neighborhood controls. Prev Med 1993;22:178-186. (Pubitemid 23150662)
22. La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995;72:244-248.
23. Banks E, Beral V, Cameron R, et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Res 2002;4:R1;doi:10.1186/bcr418. http://breast-cancer-research.com/content/4/1/ R1 [accessed 14 July 2010].
24. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269. (Pubitemid 29091853)
25. Rosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 1998;209:511-518. (Pubitemid 28503121)
26. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
27. Pukkala E, Weiderpass E. Time trends in socio-economic differences in incidence rates of cancers of the breast and female genital organs (Finland, 1971-1995). Int J Cancer 1999;81:56-61.
28. Danø H, Andersen O, Ewertz M, et al. Socioeconomic status and breast cancer in Denmark. Int J Epidemiol 2003;32:218-224. (Pubitemid 36622266)
29. Brown SB, Hole DJ, Cooke TG. Breast cancer incidence trends in deprived and affluent Scottish women. Breast Cancer Res Treat 2007;103:233-238. (Pubitemid 46789145)
30. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997;145:536-545. (Pubitemid 27111222)
31. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788-795.
32. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-945. (Pubitemid 30463571)
33. Maclure M, Greenland S. Tests for trend and dose response: misinterpretations and alternatives. Am J Epidemiol 1992;135:96-104.
34. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II - The Design and Analysis of Cohort Studies (IARC Scientific Publication No. 82). Lyon, France: International Agency for Research on Cancer, 1987.
35. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
36. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
37. Mueck AO, Seeger H, Shapiro S. Risk of breast cancer during hormone replacement therapy. Horm Biol Clin Invest 2010;3:329-339.
38. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37. (Pubitemid 36124293)
39. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;41:171-175. (Pubitemid 34211971)
40. North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society. Menopause 2003;10:113-132.